A phase III study of Dipraglurant in the treatment of Levodopa-Induced Dyskinesia associated with Parkinson's Disease

Trial Profile

A phase III study of Dipraglurant in the treatment of Levodopa-Induced Dyskinesia associated with Parkinson's Disease

Planning
Phase of Trial: Phase III

Latest Information Update: 13 Jun 2016

At a glance

  • Drugs Dipraglurant (Primary)
  • Indications Drug-induced dyskinesia; Parkinson's disease
  • Focus Registrational; Therapeutic Use
  • Sponsors Addex Therapeutics
  • Most Recent Events

    • 13 Jun 2016 According to an Addex Therapeutics media release, this trial will be supported by Michael J. Fox Foundation for Parkinsons Research (MJFF).
    • 25 Apr 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top